1[1]Braunwald E, Antman EM, Beasley JW. ACC/AHA guidelines for the ranagement of patient with unstable angina and non ST segment elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patient with Unstable Angina)[J ]. J Am Coll Cardiol, 2000,36: 970 - 1062 被引量：1
3[3]The Scandinavian Simvastatin Surrival Study Group.Randomized trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Surrival Study (4s) [ J ]. Lancet, 1994,344:1383 - 1389 被引量：1
4[4]Ridket PM, Rifai N, Pfeffer MA, et al. Inflammation,pravastatin,and the risk of coronary events after myocardial infarction in patients with average cholesteterol levels. Cholesterol and Recurrent Events(CARE)Investigators[ J ]. Circulation, 1998,98: 839 - 844 被引量：1
5[5]The Long- term Intervention with Pravastatin in Ischemic Disease Study Group. Prevention of cardiovascular events and a broad range of initial cholesterol levels[J ]. N Engl J Med, 1998,339:1349 - 1357 被引量：1
6[6]West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) [J ]. Circulation, 1998,97:1440 -1445 被引量：1
7[7]Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels; results of AFCAPS/Tex CAPS[ J ]. JAMA, 1998,279:1615 - 1622 被引量：1
9[9]Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling ( PPP ) project [ J ]. Circulation,2000,102:1893 - 1900 被引量：1
10[10]Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: A randomized clinic trial [ J ]. JAMA, 2001,285:1711 - 1718 被引量：1
